Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2- ...